Related Experiment Video
Updated: Aug 15, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
The pharmacokinetics of etanercept in healthy volunteers
J M Korth-Bradley1, A S Rubin, R K Hanna
1Clinical Pharmacokinetics, Wyeth-Ayerst Research, Philadelphia, PA 19101, USA. korthbj@war.wyeth.com
Objective:
To describe the pharmacokinetics of etanercept when administered by subcutaneous injection in single doses to healthy volunteers.
Methods:
Twenty-six healthy volunteers between 19 and 50 years of age received single doses of etanercept 25 mg by subcutaneous injection into the abdomen. Serial serum samples were collected for 21 days. An enzyme-linked immunosorbent assay with a quantitation limit of 0.3 ng/mL was used to measure the drug concentrations.
Results:
Etanercept was well tolerated by healthy volunteers. A one-compartment model was found to best describe the concentration-time data and was used to determine the pharmacokinetic parameters. Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L. The AUC was 235 +/-98 mg x h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours.
Conclusions:
Etanercept was slowly absorbed and slowly eliminated after subcutaneous administration. Dosing at the recommended rate of 25 mg twice weekly would be expected to result in concentrations of approximately 3 mg/L. Intersubject variability for apparent clearance in healthy volunteers was 64%.
Related Concept Videos
Pharmacokinetics: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

